lumiracoxib
Small moleculeexperimental
Lumiracoxib is a COX-2 selective inhibitor nonsteroidal anti-inflammatory drug. — Wikipedia
Clinical trial activity
17 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
10
Phase 3
9
Phase 4
7
Earliest trial started Nov 1, 2000 (NCT00267215)
Timeline
Indications
Approved for
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Cyclooxygenase 2 (COX2) is involved in the production of prostaglandins, in response to injury or certain diseases. These prostaglandins cause pain, swelling and inflammation. When COX2 is inhibited the production of these prostaglandins is blocked, and that relieves pain and inflammation.
It has the highest COX-2 selectivity of any NSAID.
It binds to a different site on the COX-2 enzyme than other COX-2 inhibitors.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(Nc2c(F)cccc2Cl)c(CC(=O)O)c1- Mol. weight
- 293.73 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaLumiracoxib ↗
- ChEMBLCHEMBL404108 ↗
Also known as
- 2-(2-((2-chloro-6-fluoro-phenyl)amino)-5-methyl-phenyl)acetic acid
- 2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid
- 2-((2-chloro-6-fluorophenyl)amino)-5-methylbenzeneacetic acid
- cox189
- cox189
- cox 189
- cox 189
- cox 189
- cox-189
- cox-189
- cox-189
- joicela
- joicela
- joicela
- joicela
- joicela
- lumiracoxib
- lumiracoxib
- lumiracoxib
- lumiracoxib
- lumiracoxib
- lumiracoxib
- lumiracoxib
- lumiracoxib
- lumiracoxib
- lumiracoxibum
- lumiracoxibum
- prexige
- prexige
- prexige
- prexige
- prexige
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01481610 | Phase 2 | Jan 1, 2012 | Hospital Central Sur de Pemex, PEMEX |
| NCT00419796 | Phase 4 | Nov 1, 2006 | Novartis |
| NCT00333567 | Phase 4 | Aug 1, 2006 | Novartis |
| NCT00350155 | Phase 4 | May 1, 2006 | Novartis |
| NCT00348491 | Phase 4 | Feb 1, 2006 | Novartis |
| NCT00267176 | Phase 4 | Nov 1, 2005 | Novartis, Southern Illinois Clinical Research |
| NCT00170781 | Phase 4 | Jun 1, 2005 | Novartis, Sponsor GmbH |
| NCT00170872 | Phase 3 | Nov 1, 2004 | Novartis, Sponsor GmbH |
| NCT00154219 | Phase 3 | Nov 1, 2004 | Novartis |
| NCT00170898 | Phase 4 | Nov 1, 2004 | Novartis |
| NCT00145301 | Phase 3 | Sep 1, 2004 | Novartis |
| NCT00475800 | Phase 3 | Jan 1, 2004 | Novartis |
| NCT00476034 | Phase 3 | Dec 1, 2003 | Novartis |
| NCT00367315 | Phase 3 | Sep 1, 2003 | Novartis |
| NCT00366938 | Phase 3 | Sep 1, 2003 | Novartis |
| NCT00637949 | Phase 3 | Dec 1, 2000 | Novartis |
| NCT00267215 | Phase 3 | Nov 1, 2000 | Novartis |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 16 | 16 | 2 | 2000 |
| Sponsor GmbH | Academic/Hospital | 2 | 0 | 2 | 2004 |
| Hospital Central Sur de Pemex | Academic/Hospital | 1 | 1 | 1 | 2012 |
| PEMEX | For profit | 1 | 0 | 1 | 2012 |
| Southern Illinois Clinical Research | For profit | 1 | 0 | 1 | 2005 |
5 organizations
Page 1 / 1